首发表现为双侧乳糜胸的胸腺瘤1例

2018-10-09 佚名 临床肿瘤杂志

乳糜胸一般是由于胸导管(包括其属支)损伤导致淋巴液漏出至胸腔所致胸腔积液,其中包含大量的甘油三酯及乳糜?临床上导致乳糜胸的病因包括外伤?医源性损伤及肿瘤等,而包括转移瘤在内的恶性肿瘤约占所有病因的50%?胸腺瘤导致双侧乳糜胸的病例鲜有报道,而因胸腺瘤阻塞上腔静脉及无名静脉?胸导管本身未受损伤的双侧乳糜胸患者更加少见?

乳糜胸一般是由于胸导管(包括其属支)损伤导致淋巴液漏出至胸腔所致胸腔积液,其中包含大量的甘油三酯及乳糜?临床上导致乳糜胸的病因包括外伤?医源性损伤及肿瘤等,而包括转移瘤在内的恶性肿瘤约占所有病因的50%?胸腺瘤导致双侧乳糜胸的病例鲜有报道,而因胸腺瘤阻塞上腔静脉及无名静脉?胸导管本身未受损伤的双侧乳糜胸患者更加少见?
 
病例简介

患者女性,73岁?因“胸闷伴面部浮肿2个月”于2016年3月1日就诊?2015年12月晨起后胸闷气促,自觉面部较前明显浮肿,伴轻度咳嗽,无发热?胸痛?心慌?端坐呼吸,无血尿?尿色浑浊等,数天后自行缓解?此后反复出现上述症状未就诊?
 
入院1周前再次出现胸闷及颜面部浮肿,症状较前明显,休息数天后未减轻?
 
入院查体示:无颈静脉怒张?胸壁静脉曲张?四肢水肿,浅表未触及肿大淋巴结,双下肺呼吸音减弱,叩诊呈浊音?患者既往高血压病史,口服硝苯地平片,血压控制良好?
 
门诊胸部CT示:前上纵隔肿瘤,侵及上腔静脉及无名静脉,双侧胸腔中等量积液,心包少量积液?入院后行双侧胸腔穿刺置管,左侧引出白色乳糜样胸水400ml及右侧引出粉红色乳糜样胸水900ml?
 
送检胸水常规及生化?乳糜试验?肿瘤标志物检测?肿瘤细胞镜检及细菌培养(表1)?间断经胸管每日平均引出胸液,右侧约200ml,左侧约50ml,性质同前?
 
表1 胸水实验室检查结果

 
2016年3月7日予以CT引导下经皮肿瘤穿刺活检术,穿刺组织HE染色病理示:B1型胸腺瘤;免疫组化病理结果示:CD20(-)?CD5(+)?CD1a(+)?CK20(-)?CK5/6(局部+)?CK7(局灶+)?Ki67(30%+)?LCA(2+)和TdT(+)?
 
CT检查示:肿瘤侵及上腔静脉及无名静脉?最终诊断:(1)B1型胸腺瘤Ⅲb期(Mosaoka分期),ECOG评分3分;(2)高血压1级(中危组)?
 
于2016年3月22日接受放疗,胸腺病灶及上腔静脉内瘤栓为GTV,四周外放20px,上下外放12.5px为PTV,照射DT为50Gy/25f?放疗前期由于右侧胸液每日引流量超过500ml,左侧约100ml,蛋白丢失严重,于2016年3月18日予以禁食并完全肠外营养支持?治疗后双侧胸液量减少至20ml/d,颜色为淡黄色?
 
于2016年3月29日开始恢复低脂饮食,胸液无明显增加?2016年3月31日复查B超双侧胸腔无积液,拔除胸腔引流管?2016年4月6日放疗至22Gy复查胸部CT提示肿瘤较前明显缩小,双侧无明显积液?见图1~图4?
 
A:左侧胸腔;B:右侧胸腔
▲图1双侧胸腔积液
 
A:HE染色;B:LCA
▲图2 活检穿刺组织HE染色(×200)及免疫组化(×200)

▲图3 胸水引流与放疗剂量变化图

 
A1?B1?C1:放疗前上腔静脉不同层面受压情况及胸水情况;A2?B2?C2:
放疗至22Gy上腔静脉不同层面受压情况及胸水情况
▲图4 放疗前后胸部CT检查
 
讨论

乳糜胸液是一种非炎性含有丰富甘油三酯及乳糜微粒的渗出液,其外观根据营养情况可呈乳白色?微黄色浑浊液,胸水常规检查中乳酸脱氢酶一般不升高,而有核细胞计数一般不超过1000×106/L,细胞分类以淋巴细胞为主?
 
胸导管是全身最长的淋巴管,长30~1000px,下段起始于梭形膨大的乳糜池,上行穿过主动脉裂孔进入胸腔,胸导管在胸腔内位于后纵隔,介于食管后?脊柱右前?胸主动脉和奇静脉之间?上行至第四五胸椎移向脊柱左侧,至第七颈椎弯向前入左颈内静脉或静脉角?
 
当胸导管损伤出现在第四五胸椎以下时,往往表现为右侧胸腔积液,而损伤出现位置较高时多数为左侧胸腔积液?
 
本例患者以双侧胸腔积液导致胸闷为首发症状,结合CT及病理穿刺结果,考虑胸腺瘤侵袭上腔静脉及无名静脉造成上腔静脉综合征,中心静脉压力增高后胸导管内淋巴液难以汇入,而经导管及其属支渗出导致双侧乳糜胸,其中右侧为血性且伴有核细胞明显升高,考虑为静脉压力高造成毛细血管破裂出血导致?由于乳糜液内含有大量蛋白?抗体?维生素及电解质,长期大量的乳糜液丢失可能导致患者出现严重水?电解质平衡紊乱?营养不良?免疫抑制,甚至继发严重感染,应尽早治疗?
 
乳糜胸患者常规治疗为控制饮食?进低油脂饮食或禁食?胸腔引流减轻胸闷症状?胸膜粘连以及行胸导管结扎术?但本例患者肿瘤侵及上腔静脉及无名静脉,导致双侧乳糜胸,首先治疗原发肿瘤?经放疗22Gy后肿瘤较前明显缩小,腔静脉压迫解除,胸导管回流顺畅后双侧胸腔积液明显减少,患者目前已正常进食,并顺利拔除双侧胸腔引流管,治疗效果满意?如后期再次出现严重乳糜胸而内科保守治疗不理想时,可通过胸膜固定术?胸导管结扎术等控制乳糜胸?

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663492, encodeId=c42c166349286, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Aug 27 19:06:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407497, encodeId=1607140e49714, content=<a href='/topic/show?id=bc4884191b8' target=_blank style='color:#2F92EE;'>#胸腺瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84191, encryptionId=bc4884191b8, topicName=胸腺瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0232667261, createdName=guihongzh, createdTime=Thu Oct 11 10:06:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522417, encodeId=7c89152241e05, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Thu Oct 11 10:06:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348659, encodeId=0b58348659f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Oct 09 20:22:50 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663492, encodeId=c42c166349286, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Aug 27 19:06:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407497, encodeId=1607140e49714, content=<a href='/topic/show?id=bc4884191b8' target=_blank style='color:#2F92EE;'>#胸腺瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84191, encryptionId=bc4884191b8, topicName=胸腺瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0232667261, createdName=guihongzh, createdTime=Thu Oct 11 10:06:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522417, encodeId=7c89152241e05, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Thu Oct 11 10:06:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348659, encodeId=0b58348659f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Oct 09 20:22:50 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663492, encodeId=c42c166349286, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Aug 27 19:06:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407497, encodeId=1607140e49714, content=<a href='/topic/show?id=bc4884191b8' target=_blank style='color:#2F92EE;'>#胸腺瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84191, encryptionId=bc4884191b8, topicName=胸腺瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0232667261, createdName=guihongzh, createdTime=Thu Oct 11 10:06:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522417, encodeId=7c89152241e05, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Thu Oct 11 10:06:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348659, encodeId=0b58348659f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Oct 09 20:22:50 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1663492, encodeId=c42c166349286, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Aug 27 19:06:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407497, encodeId=1607140e49714, content=<a href='/topic/show?id=bc4884191b8' target=_blank style='color:#2F92EE;'>#胸腺瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84191, encryptionId=bc4884191b8, topicName=胸腺瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0232667261, createdName=guihongzh, createdTime=Thu Oct 11 10:06:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522417, encodeId=7c89152241e05, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Thu Oct 11 10:06:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348659, encodeId=0b58348659f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Oct 09 20:22:50 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
    2018-10-09 医者仁心5538

    学习了

    0

相关资讯

Schizophr Res:首发精神疾病治愈后停药:谁可以停?何时停?如何停?

首发精神病患者在有效治疗后,应该维持抗精神病药物多长时间,这仍然是一个有争议和未解决的问题,它也具有重要的临床意义。

汤钊猷:《中国式抗癌――孙子兵法中的智慧》 开启肝癌科普

图为汤钊猷院士在上海图书馆演讲厅给读者签名时场景 孙国根摄 4月27日,年过八十的国际著名肝癌研究学者、复旦大学肝癌研究所所长、从事癌症研究和临床实践40余年的知名院士汤钊猷亲自来到上海图书馆,为读者签售刚由上海科技出版社出版的抗癌科普新著――《中国式抗癌――孙子兵法中的智慧》,受到市民欢迎。 本书从启动到完稿长达两年,书中,汤钊猷在书中融汇东西方思维精髓,